Public Advisory - Sivem ezetimibe 10 mg tablets: One lot recalled as some bottles may contain perindopril 4 mg tablets Français
Product: Sivem ezetimibe 10 mg tablets
Issue: Health products – Product safety
What to do: If your bottle of ezetimibe 10 mg tablets contains any perindopril 4 mg tablets, or if you are unsure, return it to your pharmacy immediately. If you are unable to return your tablets to the pharmacy right away, talk to your pharmacist or doctor for further guidance. Seek immediate medical attention if you are experiencing serious side effects, including symptoms of a severe allergic reaction, such as difficulty breathing or swallowing or severe swelling of the lips, mouth or throat.
Affected products
Issue
Sivem Pharmaceuticals ULC is recalling one lot of Sivem ezetimibe 10 mg tablets because some bottles may also contain perindopril 4 mg tablets. Taking perindopril when prescribed ezetimibe may pose serious health risks.
Ezetimibe is a prescription drug used by adults and children 10 years of age and older to lower cholesterol and other fats in the blood. Perindopril is a prescription drug used in adults to treat high blood pressure.
Patients not normally prescribed perindopril may experience side effects such as a drop in blood pressure, dizziness, light-headedness or fainting. Other possible effects could include headache, cough, or gastrointestinal discomfort (e.g., nausea, vomiting or diarrhea). The risk can be higher in people with low blood pressure, kidney problems, or those taking other medications that affect blood pressure. Patients unknowingly taking a medication could also have a severe allergic reaction to that medication.
Health Canada is monitoring the company's recall and investigation, including its implementation of corrective and preventive actions to prevent this issue from reoccurring. The Department will inform the public if any new health risks are identified.
What you should do
Check your medication bottle to ensure it only contains Sivem ezetimibe 10 mg tablets.
Sivem ezetimibe 10 mg is a white oblong tablet, with "93" stamped on one side and "A11" on the other.
Perindopril 4 mg is a spotted light green oblong tablet, with "4" stamped on one side and nothing stamped on the other. The tablet is scored (indented) on both middle edges.
If the bottle contains any unusual tablets, or if you are unsure, return it to your pharmacy immediately. Your pharmacist will check the tablets and provide you with a replacement, if needed.
If you are unable to return your tablets to the pharmacy right away, talk to your pharmacist or doctor for further guidance.
Seek immediate medical attention if you are experiencing serious side effects (e.g., dizziness, light-headedness or fainting, or severe allergic reaction).
If you have questions about this recall, contact Sivem Pharmaceuticals by calling 1-855-757-4836 or by emailing [email protected].
Report any health product-related side effects or complaints to Health Canada.
Additional information for health professionals:
Health care professionals, such as pharmacists, should check bottles of Sivem ezetimibe 10 mg tablets before dispensing to ensure they do not contain perindopril 4 mg tablets. Report any unusual bottles or other issues to the company and to Health Canada.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
19 hours ago
- Cision Canada
Health Canada launches public consultation on proposed changes to increase oversight of precursor chemicals and drug equipment
OTTAWA, ON, June 27, 2025 /CNW/ - The Government of Canada is taking action to keep communities safe on both sides of the border. This includes detecting and disrupting the illegal fentanyl trade. Today, the Minister of Health, Marjorie Michel, launched a 45-day public consultation on proposed changes to how Canada regulates precursor chemicals and devices such as pill presses and encapsulators that could be used in the illegal production of drugs. The consultation is open until August 12, 2025. The public consultation will allow impacted stakeholders, such as regulated industries that use precursors for legitimate uses, pharmacies and individual pharmacists, to provide feedback on the proposed changes. These changes would strengthen controls around precursor chemicals and drug equipment to support law and border enforcement as they take action to stop their illegal importation and distribution. Quotes "Our government is acting to protect Canadians against illegal synthetic drugs like fentanyl. By working with the industry and our partners, we are making our streets safer." The Honourable Marjorie Michel Minister of Health "Keeping communities safe from the harms of illegal drugs is a top priority. Together with our Strong Borders bill, these proposed changes will give law enforcement and border officers stronger tools to stop the illegal production and trafficking of dangerous substances like fentanyl. We are committed to working with our partners to disrupt organized crime, further secure our borders and protect Canadians." The Honourable Gary Anandasangaree Minister of Public Safety "Step by step we are increasing pressure on organized crime groups and sending a clear message: Canada will not tolerate illegal drugs in our communities and at our borders. We will use every tool at our disposal to support law and border enforcement as they tackle the production and distribution of illegal drugs." Kevin Brosseau Fentanyl Czar Quick Facts Under the Controlled Drugs and Substances Act (CDSA), the Precursor Control Regulations (PCR) sets rules for the use of precursor chemicals. While some precursors have legitimate uses, they can also be used in the illegal production of controlled substances, like fentanyl and fentanyl analogues. In Canada, precursors are controlled under Schedule VI of the CDSA and are regulated under the PCR. To ensure that law and border enforcement have the tools they need to detect and address fentanyl and its precursors, the federal government is investing $78.7 million to expand Health Canada's laboratory and regulatory capabilities. Health Canada's Precursor Chemical Risk Management Unit provides better oversight into precursor chemicals and their distribution channels, and enhance monitoring and surveillance of illegal drug trends to enable timely law enforcement action. Health Canada is establishing a new Canadian Drug Analysis Centre that will allow for more specialized analysis of synthetic drug samples. The analysis will help determine how and where these substances were manufactured to support law enforcement and public safety partners to strategically target organized crime. Notice of Intent on this regulatory proposal to enhance oversight of precursor chemicals and drug equipment was open for public consultation from January 31 to March 3, 2025. 1S7Oa6kfqPnSMg%3D&rese SOURCE Health Canada (HC)
Cision Canada
20 hours ago
- Cision Canada
Public Advisory - Unauthorized blood glucose monitors sold online may pose serious health risks Français
Product: Unauthorized blood glucose monitors, also referred to as glucose-reading devices or non-invasive glucose monitors Issue: Health products - Unauthorized product; Medical devices - Inaccurate test or measurement results What to do: Do not use glucose monitors that have not been authorized by Health Canada. Consult a healthcare professional if you have used an unauthorized glucose monitor and have health concerns. Only use devices listed on Health Canada's Medical Device Active Licence Listing (MDALL). Issue Health Canada is warning people with diabetes and their caregivers that numerous unauthorized blood glucose monitors are being sold through social media and online stores. Unauthorized products have not been assessed for safety and effectiveness and may pose serious health risks to consumers because they may give false blood glucose readings or may not provide timely alerts, which could lead to errors in diabetes management. Errors may include: taking too little insulin, which can lead to high blood sugar (called hyperglycemia), taking too much insulin, which can lead to low blood sugar (called hypoglycemia), and failing to treat low or high blood sugar. These errors could lead to serious health consequences requiring medical treatment, such as hyperglycemic emergencies, severely low blood sugar, loss of consciousness, seizures, coma, and death. These unauthorized devices are being marketed using various descriptions, including glucose-reading devices, blood glucose monitoring systems, non-invasive glucose/health monitors, non-invasive blood glucose meters/monitors, and glucose and vital signs monitors. While some of these unauthorized devices claim to measure glucose levels non-invasively (without puncturing the skin or inserting a device into the body), consumers should be aware that at this time, Health Canada has not authorized the sale of any non-invasive blood glucose monitoring devices. In addition, some of the promotional material for these unauthorized products contain false endorsements from Health Canada using its corporate signature. Health Canada does not endorse health products and does not allow its corporate signature to appear on health or consumer product advertising. Consumers can search Health Canada's Medical Device Active Licence Listing (MDALL) to determine whether a blood glucose monitor has been authorized by the department. Health Canada will continue to take necessary action to stop the sale and advertising of these unauthorized products in Canada. What you should do Only use blood glucose monitors that have been authorized by Health Canada. If you suspect that you are using an unauthorized product, stop using it immediately and replace it with an authorized monitor. Talk to your health care provider about which blood glucose monitor is right for you. Only use devices listed on Health Canada's Medical Device Active Licence Listing (MDALL). Report any health product-related side effects or complaints to Health Canada.
Global News
a day ago
- Global News
Prince Edward Island's chief public health office confirms two new cases of measles
Prince Edward Island is reporting two cases of measles in unvaccinated or partially vaccinated people. The Island's public health office says the infected individuals had visited a number of places since June 21, potentially exposing other people to the highly infectious virus. As a result, the province has produced a list of locations considered potential exposure sites. The 10 locations include the Charlottetown Airport on June 25 and West Jet flights the same day from Kamloops, B.C., to Calgary, and from Calgary to Charlottetown. Other locations on the Island include service stations in Stanley Bridge and Scotchfort, a chapel in Charlottetown and a number of retail outlets in Charlottetown and Morell. As of June 14, Health Canada was reporting 3,381 cases of measles across Canada since the beginning of the year. Ontario was reporting 2,186 cases and Alberta had 961 cases. The two provinces accounted for 93 cent of all cases. Story continues below advertisement 2:05 Rising measles cases could lead to more problems down the road Measles spreads through the air and close contact, such as breathing, coughing or sneezing — and it can cause a serious illness that may require admission to a hospital. Get weekly health news Receive the latest medical news and health information delivered to you every Sunday. Sign up for weekly health newsletter Sign Up By providing your email address, you have read and agree to Global News' Terms and Conditions and Privacy Policy Symptoms include fever, coughing, runny nose, red eyes and a blotchy, red rash that appears three to seven days after the fever starts. Vaccination against measles is close to 100 per cent effective in preventing the disease. Health Canada says measles was eliminated in the country in 1998, but recent outbreaks in Alberta have been the most severe in almost 40 years. Across the country, 46 per cent of infections have been reported among those between the ages of 5 and 17, followed by those between the ages of 18 and 54 at 27 per cent. Meanwhile, Ontario reported its first death related to a measles outbreak on June 5. Ontario officials confirmed that a premature baby died after being infected in the womb of their unvaccinated mother. Story continues below advertisement On Wednesday, British Columbia Premier David Eby said the spread of measles is the predictable outcome of the 'recklessness' of anti-vaccination politicians. He told a Vancouver news conference that the focus for provincial public health authorities must be making sure people who are not protected receive vaccinations. 'I will encourage all British Columbians to ensure that they are vaccinated,' Eby said. 'Measles is no joke. It kills kids. It's a preventable disease, and we don't want that to be the story of the summer for our province.' This report by The Canadian Press was first published June 27, 2025.
